NCT06055452View on ClinicalTrials.gov

Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 19, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions
Pre-Heart FailureHypertension
Interventions
DRUG

Empagliflozin 10 MG

Each participant in the empagliflozin treatment group takes a daily dose of 10mg.

DRUG

Placebo

Each participant in the placebo group takes matching placebo.

Trial Locations (2)

100037

RECRUITING

Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing

518038

RECRUITING

Fuwai Hospital Chinese Academy of Medial Sciences, Shenzhen, Shenzhen

All Listed Sponsors
lead

China National Center for Cardiovascular Diseases

OTHER_GOV